ReviewClinical microbiology reviews2013
Antianaerobic antimicrobials: spectrum and susceptibility testing.
Review in Clinical microbiology reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05852158 (The Use of Single Dose vs Short-Term Peri-Operative Cefazolin in the Prevention of Surgical Site Infection Following Orthognathic Surgery), which is not on this map. Cited by 130 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Single Dose vs Short-Term Peri-Operative Cefazolin in the Prevention of Surgical Site Infection Following Orthognathic Surgery
Who cites it
130 citing papers in PubMed.
- Re-incubation of positive anaerobic blood culture bottles for detecting additional anaerobes in polymicrobial bacteremia.Microbiology spectrum · 2026Observational
- Artificial Intelligence-Empowered Single-Cell Phenotyping for Rapid, Automated Pathogen Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Safety ofEFSA journal. European Food Safety Authority · 2026Article
- Gut microbiome features associated with vancomycin-resistant Enterococcus acquisition in intensive care unit patients.Annals of clinical microbiology and antimicrobials · 2026Article
- Antimicrobial resistance and genetic characterization ofOne health (Amsterdam, Netherlands) · 2026Article
- Antibiotic-induced microbiota disruption impairs neutrophil-mediated immunity to respiratorymBio · 2026Article
- Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.Nature medicine · 2026Article
- Bioactive peptides in Endodontic infections: The Good, The Bad, and The Ugly.Probiotics and antimicrobial proteins · 2026Review
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Antibiotics with anaerobic coverage are associated with disproportionate gut microbiota disruption in ICU patients: a multi-centre, longitudinal observational study.Intensive care medicine · 2025Article
- Microbiome and resistome characterization of patients colonized with carbapenem-resistant Enterobacterales by long-read metagenomic next-generation sequencing of rectal swabs.JAC-antimicrobial resistance · 2025Article
- Assessing Clinical Outcomes of Metronidazole for Intra-Abdominal Infections When Dosed Every 12 h Versus Every 8 h in a Multi-Center Health System.Antibiotics (Basel, Switzerland) · 2025Article
- A high-throughput anaerobic method for viability assays.Microbiology spectrum · 2025Article
- Alistipes Bacteremia in Older Patients with Digestive and Cancer Comorbidities, Japan, 2016-2023.Emerging infectious diseases · 2025Review
- Understanding the Relationship Between Cerebrovascular Disease and the Gut Microbiome.Stroke (Hoboken, N.J.) · 2025Review
- Effects of Prolonged Antibiotic Therapy in Lung Abscesses-Analysis of Case Series.Case reports in pulmonology · 2025Article
- Article
- Direct, Broad-Spectrum Antimicrobial Activity of AgMaterials (Basel, Switzerland) · 2024Article
- Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer.Molecular biomedicine · 2024Article
- Metabolic changes associated with polysaccharide utilization reduce susceptibility to some β-lactams inmSphere · 2024Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Susceptibility testing of anaerobic bacteria recovered from selected cases can influence the choice of antimicrobial therapy. The Clinical and Laboratory Standards Institute (CLSI) has standardized many laboratory procedures, including anaerobic susceptibility testing (AST), and has published documents for AST. The standardization of testing methods by the CLSI allows comparisons of resistance trends among various laboratories. Susceptibility testing should be performed on organisms recovered from sterile body sites, those that are isolated in pure culture, or those that are clinically important and have variable or unique susceptibility patterns. Organisms that should be considered for individual isolate testing include highly virulent pathogens for which susceptibility cannot be predicted, such as Bacteroides, Prevotella, Fusobacterium, and Clostridium spp.; Bilophila wadsworthia; and Sutterella wadsworthensis. This review describes the current methods for AST in research and reference laboratories. These methods include the use of agar dilution, broth microdilution, Etest, and the spiral gradient endpoint system. The antimicrobials potentially effective against anaerobic bacteria include beta-lactams, combinations of beta-lactams and beta-lactamase inhibitors, metronidazole, chloramphenicol, clindamycin, macrolides, tetracyclines, and fluoroquinolones. The spectrum of efficacy, antimicrobial resistance mechanisms, and resistance patterns against these agents are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.